AbCellera Biologics Inc. (ABCL)

NASDAQ: ABCL · Real-Time Price · USD

11.36

+0.08 (0.71%)

At close: Sep 2, 2026, 4:00 PM EDT

11.29

-0.07 (-0.62%)

Pre-market: Sep 3, 2026, 4:00 AM EDT

AbCellera Biologics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	66.17	75.13	28.83	38.03	485.42	375.2
Revenue Growth	101.27%	160.56%	-24.17%	-92.17%	29.38%	60.92%
Cost of Revenue	197.77	186.83	167.26	175.66	174.32	107.58
Gross Profit	-131.6	-111.7	-138.43	-137.63	311.11	267.63
Selling, General & Admin	68.36	83.23	85.49	75.18	66.76	48.76
Operating Expenses	93.56	105.4	144.34	99.57	86.2	63.21
Operating Income	-225.16	-217.1	-282.77	-237.21	224.91	204.41
Interest & Investment Income	16.86	28.33	38.47	42.25	16.08	3.33
Other Non Operating Income (Expenses)	10.53	10.18	11.2	17.03	8.21	11.91
EBT Excluding Unusual Items	-197.77	-178.6	-233.1	-177.93	249.2	219.65
Gain (Loss) on Sale of Investments	1	1	17.4	3.9	-1.7	-0.5
Asset Writedown	-	-	-32	-	-8.4	-
Other Unusual Items	-	-	47.3	-	-	-
Pretax Income	-196.77	-177.6	-200.4	-174.03	239.1	219.15
Income Tax Expense	-32.11	-31.18	-37.54	-27.63	80.58	65.69
Net Income	-164.66	-146.41	-162.86	-146.4	158.52	153.46
Net Income to Common	-164.66	-146.41	-162.86	-146.4	158.52	153.46
Net Income Growth	-	-	-	-	3.29%	80.33%
Shares Outstanding (Basic)	302	299	294	289	285	276
Shares Outstanding (Diluted)	302	299	294	289	315	318
Shares Change	1.74%	1.49%	1.79%	-8.15%	-1.09%	20.96%
EPS (Basic)	-0.55	-0.49	-0.55	-0.51	0.56	0.56
EPS (Diluted)	-0.55	-0.49	-0.55	-0.51	0.50	0.48
EPS Growth	-	-	-	-	4.17%	6.21%

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-119.67	-174.07	-186.95	-120.82	206.7	186.13
Free Cash Flow Per Share	-0.40	-0.58	-0.64	-0.42	0.66	0.58
Gross Margin	-198.88%	-148.68%	-	-	64.09%	71.33%
Operating Margin	-340.27%	-288.98%	-980.70%	-623.82%	46.33%	54.48%
Profit Margin	-248.84%	-194.88%	-564.83%	-385.00%	32.66%	40.90%
Free Cash Flow Margin	-180.85%	-231.69%	-648.40%	-317.75%	42.58%	49.61%
EBITDA	-199.96	-194.93	-223.92	-212.81	244.35	218.88
EBITDA Margin	-	-259.47%	-	-	50.34%	58.34%
D&A For EBITDA	25.2	22.17	58.85	24.4	19.44	14.47
EBIT	-225.16	-217.1	-282.77	-237.21	224.91	204.41
EBIT Margin	-	-288.98%	-	-	46.33%	54.48%
Effective Tax Rate	-	-	-	-	33.70%	29.97%
Revenue as Reported	66.17	75.13	28.83	38.03	485.42	375.2

SEC Filings: 10-K · 10-Q